UP FRONT
and Boston Children’s Hospital. He also
served as director of pediatric hematology/oncology at Children’s Hospital
Medical Center in Cincinnati, Ohio, and
director and professor of pediatric oncology and professor of oncology and pediatrics at Johns Hopkins University School
of Medicine in Baltimore, Maryland.
Robert L. Meyer, president and chief
executive officer of Phoenix Children’s
Hospital said: “The tragic and sudden
loss of Dr. Arceci has touched the Phoenix
Gerald L. Logue, MD
Children’s family deeply. Bob was known
around the world as a brilliant cancer
researcher and a skilled and compassionate pediatric oncologist. We will miss him,
but the loss is felt most deeply by his dear
family. We extend our heartfelt condolences to Bob’s wife Jean, who is also a
member of the Phoenix Children’s family,
his two sons, and his extended family and
network of friends and colleagues.”
(1941-2015)
Gerald L. Logue, MD, professor of medicine
and chief of hematology at the University
of Buffalo School of Medicine and Biomedical Sciences, passed away suddenly
on June 7. Dr. Logue, who was known for
his commitment to medical training, had
practiced medicine in Buffalo since 1982.
Dr. Logue devoted himself to supporting and enhancing the dialogue regarding
T:7”
4.2 Allergic Reactions
REVLIMID is contraindicated in patients who have demonstrated
hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic
epidermal necrolysis) to lenalidomide [see Warnings and Precautions
(5.8)].
5.2 REVLIMID REMS™ Program
Because of the embryo-fetal risk [see Warnings and Precautions (5.1)],
REVLIMID is available only through a restricted program under a Risk
Evaluation and Mitigation Strategy (REMS), the REVLIMID REMS™
program (formerly known as the “RevAssist®” program).
Required components of the REVLIMID REMS™ program include the
following:
• Prescribers must be certified with the REVLIMID REMS™ program by
enrolling and complying with the REMS requirements.
• Patients must sign a Patient-Physician agreement form and comply
with the REMS requirements. In particular, female patients of
reproductive potential who are not pregnant must comply with the
pregnancy testing and contraception requirements [see Use in Specific
Populations (8.6)] and males must comply with contraception
requirements [see Use in Specific Populations (8.6)].
• Pharmacies must be certified with the REVLIMID REMS™ program,
must only dispense to patients who are authorized to receive REVLIMID
and comply with REMS requirements.
Further information about the REVLIMID REMS™ program is available at
www.celgeneriskmanagement.com or by telephone at 1-888-423-5436.
5.3 Hematologic Toxicity
REVLIMID can cause significant neutropenia and thrombocytopenia.
Monitor patients with neutropenia for signs of infection. Advise patients to
observe for bleeding or bruising, especially with use of concomitant
medication that may increase risk of bleeding. Patients taking REVLIMID
should have their complete blood counts assessed periodically as
described below [see Dosage and Administration (2.1, 2.2, 2.3)].
Patients taking REVLIMID in combination with dexamethasone for MM
should have their complete blood counts (CBC) assessed every 7 days
(weekly) for the first 2 cycles, on Days 1 and 15 of Cycle 3, and every
Patients taking REVLIMID for MDS should have their complete blood counts
monitored weekly for the first 8 weeks and at least monthly thereafter.
Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled
in ѡ